The validity of Celgene’s patent 7,968,569 won’t be reviewed by the Patent Trial and Appeal Board, the review board said in a notice posted on its electronic docket.

Alvogen had to prove that it had a “reasonable likelihood” of winning its argument that the patent didn’t cover a new idea and never should have issued.

The patent covers a dosing regimen to treat multiple myeloma, a rare and stubborn blood cancer.

Alvogen argued that it was “standard practice to administer...